gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin data batten diseas
highlight week juli august neutral announc interim data
phase i/ii trial batten diseas patient treat singl
intrathec dose vg/kg patient reach month post-treat
maintain hamburg score initi chang point follow stabil data batten
diseas natur histori studi show least declin hamburg score month
patient studi unrat announc interim result singl ascend dose sad portion
phase i/ii trial mrna therapeut cystic fibrosi cf mean chang
baselin percent predict forc expiratori volum one second day sd placebo
sd dose group sd dose group sd
dose group base result propos protocol chang submiss fda includ
addit dose cohort sad part trial includ dose cohort longer
includ dose cohort multipl ascend dose mad part trial buy chardan
top pick announc licens agreement unrat grant non-exclus
world-wide licens right sublicens vector develop commerci
treatment friedreich ataxia fa receiv up-front payment entitl futur royalti
gene therapi develop use licens intellectu properti ip crispr
buy announc result provid clinic updat includ initi enrol phase i/ii trial
allogen car-t cell malign gene edit allogen
car-t hit clinic non-hodgkin lymphoma nhl follow heel precis bioscienc unrat
allogen unrat began trial
look forward august august compani report result arbutu biopharma buy august
august et buy chardan top pick august et
intrexon corpor unrat august et buy august market close
weekli price move vivo genet medicin aav srna mrna vivo gene edit
mrna mm vivo gene edit mm contributor buy mm
upcom chardan genet medicin event contact chardan rsvp
pleas refer import disclosur inform regul analyst certif found page report
gene edit see limit read-across nuclease-fre edit controversi juli livshit
juli research univers southern california post manuscript biorxiv preprint server
outlin unsuccess effort reproduc effici nuclease-fre genom edit clade aav vector base
public unrat report edit similar aav vector isol
hematopoiet stem cell aavhsc
increas attent drawn preprint may sent homolog share price market close
juli view data reproduc core element scientif process caution draw wide-
rang conclus non-peer-review studi diverg experiment detail
see limit read-across logicbio buy usc studi logicbio platform design
work within homolog recombin frequenc report aav vector
crsp buy allo car-t trial activ tdt/scd data juli livshit
crispr announc result provid clinic updat includ initi enrol
phase i/ii trial allogen car-t cell malign compani
also announc updat phase i/ii program sever transfusion-depend beta thalassemia tdt
sickl cell diseas scd patient dose on-going studi
gene edit allogen car-t hit clinic non-hodgkin lymphoma nhl follow
heel precis bioscienc unrat allogen unrat
began trial approach yield highest degre car-t expans
longest persist along time-fram persist actual need achiev durabl respons
allogen cell-bas therapi us remain open question field
buy steadi progress attr data pipelin august livshit
intellia report result updat guidanc vivo ex vivo program catalyst
guidanc ind submiss lead vivo transthyretin amyloidosi attr program
refin pre-ind meet fda initi toxicolog studi compani
re-affirmed plan nomin develop candid acut myeloid leukemia aml
see multipl potenti direct intellia next vivo program compani weigh option priorit
import preclin aml studi advanc ex vivo front particularli interest detail
regard specif design lead candid respect target tcr insert highlight
may research target insert construct cell receptor alpha trac gene shown
improv function set car-t cell construct deliv lentiviru yet
clear extent target tcr insert would offer advantag
genet medicin news juli august
sln gb unrat announc appoint dr steven romano board director juli
prqr buy receiv ema prime design oligonucleotide-bas tx sepofarsen juli
ortx unrat receiv fda rmat design ex vivo lentivir gt juli
qure buy report result highlight recent progress gt program juli
onc unrat receiv us patent cytokine-bas intratumor immunotherapi juli
unrat announc mm warrant exercis privat placement exist sharehold juli
unrat publish new strategi optim specif gene edit nucleas juli
stanford publish dataset-en predict repair gene edit cell juli
unrat report result highlight pipelin progress juli
unrat report result provid corpor updat juli
buy file announc resign mathew bazley gener counsel juli
nbse unrat announc addit dr samuel broder dr georg church sab juli
rgl unrat announc appoint cri calsada chief offic juli
page
lonn unrat partner vineti privat suppli chain optim gt manufactur juli
xcur buy announc price mm public offer uplist nasdaq capit market juli
chop publish sensit screen method transgen express aav vector juli
unrat announc partnership nci pi/ii trial cell tx juli
buy announc licens agreement unrat gt fa juli
announc entri licens agreement term agreement
grant non-exclus world-wide licens right sublicens vector develop
commerci treatment fa
receiv up-front payment potenti receiv on-going fee develop
commerci mileston payment royalti net sale product incorpor licens intellectu properti
note program use vector gt
duchenn muscular dystrophi dmd
unrat announc interim result pi/ii trial mrna tx cystic fibrosi juli
announc interim result phase i/ii trial mrna therapeut
encod cftr protein cf result announc sad portion trial
patient receiv singl dose placebo per group via nebul
primari measur lung function assess day post-treat mean chang
baselin day sd placebo sd dose group sd
dose group sd dose group
treatment-rel seriou advers event sae patient dose group
experienc transient mild moder febril reaction approxim hour post-dos deem
relat studi drug patient dose group experienc treatment-rel advers event classifi
pulmonari exacerb occur day post-treat
result repres clinic data inhal mrna therapeut base result
propos follow protocol chang submiss fda includ addit dose cohort
sad part trial includ dose cohort longer includ dose cohort
mad part trial mad result expect
unrat report result provid busi updat juli
neutral file amend extend tender offer roch unrat sep juli juli
unrat report result provid corpor updat juli
unrat announc appoint gari loeb evp gener counsel juli
bluespher privat announc appoint dr david apelian ceo juli
fred hutch publish crispr-bas gene edit hsc increas amount fetal hemoglobin juli
neutral announc interim data pi/ii trial aav-bas gt batten diseas august
trial
batten diseas amicu plan present analys data analyst day plan
well child neurolog societi annual meet octob charlott nc
patient treat singl intrathec dose vg/kg data announc
patient reach month post-treat patient age month enrol
patient maintain score hamburg scale measur motor languag function initi
chang point follow stabil oldest patient treat age month show declin
see slide pair treat sibl younger sibl demonstr better outcom compar
older sibl data natur histori studi show least declin
hamburg score month patient studi
treat patient rang month post-treat advers event sae report
sae deem treatment-rel amicu report pattern advers event relat
immunogen
phase
adap unrat report result provid corpor updat august
adap unrat announc chang execut team august
page
ise neutral report result highlight pipelin progress august
nejm publish articl gt pioneer kathi high review statu gt field august
arct buy receiv mm commit cystic fibrosi foundat mrna tx cf august
arct buy announc mm direct offer common stock august
neutral announc departur cso dr mehdi gasmi board member dr mitchel finer august
unrat report result provid busi updat august
unrat report result provid corpor updat august
unrat report result highlight pipelin progress august
sirion privat announc result complet techshar program euronext august
tng fp unrat announc partner sillajen privat discontinu piii trial ov pexa-vec august
arct buy announc mm privat placement common stock august
compani mention report
page
select catalyst genet medicin coverag
dose patient phase studi mp
provid updat phase i/ii studi hemophilia
dcr-phxc initi long-term registr roll-ov studi ph
aro-aat initi phase ii/iii studi liver diseas
lumasiran initi illuminate-c phase trial
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
initi phase ii trial /- cemiplimab cutan squamou cell carcinoma
initi phase trial /- solid tumor
initi phase i/ii trial dmd
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
submit ind methylmalon acidemia mma
present data phase portion solid tumor trial /- nivolumab
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi phase i/ii trial autosom recess congenit ichthyosi
initi dose phase trial hemophilia
provid updat priorit program sjogren syndrom al wet
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
present preclin data new gt program fabri pomp defici
provid follow-up data piib dose-confirm studi hemb
initi phase i/ii trial
file ind cta pomp diseas
present top-lin data phase i/iia clinic trial wet
 fc report final analysi phase trial rhgg
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
figur alnylam/mdco meiragtx replimun solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
initi phase trial recess dystroph epidermolysi bullosa
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
begin patient dose phase trial
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valrox present full piii top-line data hem
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
zolgensma anticip approv eu
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
valrox submit bla pend fda feedback hemophilia
initi pivot phase trial rdeb
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase i/ii trial leukocyt adhes deficiency-i
report initi phase data process fanconi anemia
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
initi phase studi pyruv kinas defici pkd
initi phase i/ii trial parkinson diseas mutat
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
rituximab report preliminari phase cohort expans data r/r nhl
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end august vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm spark genet therapytickerratingccm ptupsideclosechang changemc mm translat gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
